|
|
||||||||
MUCOSAL BIOLOGY
-mediated apoptosis
The Jack Bell Research Centre, Vancouver, British Columbia, Canada V6H 3Z6
Submitted 6 May 2003 ; accepted in final form 24 June 2003
Tumor necrosis factor-
(TNF-
) is a multifunctional cytokine involved in the expression of many genes integral to the inflammatory response. In addition, it activates both apoptotic and survival pathways, the latter being mediated through the activation of the transcription factor nuclear factor-
B (NF-
B). Protein kinase CK2, a serine-threonine kinase that is universally upregulated in human malignancies, may be involved at multiple levels in this process. However, its role in mediating a survival response within colon cancer cells remains incompletely understood. Here we report that inhibition of CK2 in HCT-116 and HT-29 cells with the use of two specific CK2 inhibitors, 5,6-dichloro-ribifuranosylbenzimidazole (DRB) and apigenin, effected a synergistic reduction in cell survival when used in conjunction with TNF-
. Furthermore, there was a demonstrable synergistic reduction in colony formation in soft agar with the use of the same combinations. Western blot analysis showed that poly-ADP ribose polymerase and procaspase-3 cleavage complemented the fluorescence-activated cell sorter analysis findings of significantly increased subdiploid DNA-containing cell populations using these conditions. Remarkably, these events occurred in the absence of any reduction in the expression of the Bcl-2 family members Bcl-2, Mcl-1, and Bcl-xL or any change in the proapoptotic molecules Bad or Bax. One-hybrid NF-
B promoter assays utilizing a Gal4-p65 transactivation domain construct revealed that the TNF-induced transactivation was inhibited by both DRB and apigenin. This was associated with a concomitant reduction in the expression of a recognized anti-apoptotic NF-
B target, manganese superoxide dismutase, demonstrated by Q-PCR. Our findings indicate a potentially novel strategy for the treatment of colon cancer, one that targets CK2 simultaneous with TNF-
administration.
CK2; tumor necrosis factor-
; apoptosis; nuclear factor-
B; manganese superoxide dismutase
This article has been cited by other articles:
![]() |
G. Sethi, B. Sung, and B. B. Aggarwal Nuclear Factor-{kappa}B Activation: From Bench to Bedside Experimental Biology and Medicine, January 1, 2008; 233(1): 21 - 31. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Van Waes Nuclear Factor-{kappa}B in Development, Prevention, and Therapy of Cancer Clin. Cancer Res., February 15, 2007; 13(4): 1076 - 1082. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Hubert, S. Paris, J.-P. Piret, N. Ninane, M. Raes, and C. Michiels Casein kinase 2 inhibition decreases hypoxia-inducible factor-1 activity under hypoxia through elevated p53 protein level J. Cell Sci., August 15, 2006; 119(16): 3351 - 3362. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Yu, J. Yeh, and C. Van Waes Protein Kinase Casein Kinase 2 Mediates Inhibitor-{kappa}B Kinase and Aberrant Nuclear Factor-{kappa}B Activation by Serum Factor(s) in Head and Neck Squamous Carcinoma Cells. Cancer Res., July 1, 2006; 66(13): 6722 - 6731. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |